Skip to main content Accessibility help
×
Home

Antiglucocorticoids in psychiatry

  • Sean A. McIsaac, Åsa Westrin and Allan H. Young

Summary

Significant evidence has accrued suggesting that the hypothalamic–pituitary–adrenal (HPA) axis plays a role in some psychiatric disorders. This article reviews the physiology of the HPA axis, evidence of dysfunction in this axis in psychiatric illnesses and the role that this dysfunction might play in pharmacological treatment resistance. Future therapeutic strategies that may potentially arise from these researches are briefly outlined.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Antiglucocorticoids in psychiatry
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Antiglucocorticoids in psychiatry
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Antiglucocorticoids in psychiatry
      Available formats
      ×

Copyright

Corresponding author

Professor Allan Young, Institute of Mental Health, University of British Columbia, 5950 University Blvd, Vancouver, BC, V6T 2A1, Canada. Email: alyoung@interchange.ubc.ca

Footnotes

Hide All

For a commentary on this article see pp. 250–252, this issue.

Declaration of Interest

A.Y. holds related grants from the Stanley Medical Research Institute and the Medical Research Council (UK) and has filed a provisional patent concerning the use of antiglucocorticoids as an adjunctive to antidepressant therapies.

Footnotes

References

Hide All
Arana, GW, Santos, AB, Laraia, MT et al (1995) Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. American Journal of Psychiatry; 152: 265–7.
Arato, M, Banki, CM, Bissette, G et al (1989) Elevated CSF CRF in suicide victims. Biological Psychiatry; 25: 355–9.
Belanoff, JK, Rothschild, AJ, Cassidy, F et al (2002) An open label trial of C–1073 (mifepristone) for psychotic major depression. Biological Psychiatry; 52: 386–92.
Board, F, Wadeson, R, Persky, H (1957) Depressive affect and endocrine functions: blood levels of adrenal cortex and thyroid hormones in patients suffering from depressive reactions. Archives of Neurology and Psychiatry; 78: 612–20.
Broadbear, JH, Winger, G, Rivier, JE et al (2004) Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology; 29: 1112–21.
Cardounel, A, Regelson, W, Kalimi, M (1999) Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proceedings of the Society for Experimental Biology and Medicine; 222: 145–9.
Cavanagh, JTO, van Beck, M, Muir, W et al (2002) Case–control study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. British Journal of Psychiatry; 180: 320–6.
Coryell, W, Young, E, Carroll, B (2006) Hyperactivity of the hypothalamic–pituitary–adrenal axis and mortality in major depressive disorder. Psychiatry Research; 142: 99104.
Cowen, PJ (2002) Cortisol, serotonin and depression: all stressed out? British Journal of Psychiatry; 180: 99100.
DeBattista, C, Belanoff, J (2005) C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease. Current Alzheimer Research; 2: 125–9.
Delva, NJ, Matthews, DR, Cowen, PJ (1996) Brain serotonin (5-HT) neuroendocrine function in patients taking cholesterol-lowering drugs. Biological Psychiatry; 39: 100–6.
Dinan, TG (1996) Serotonin and the regulation of hypothalamic–pituitary–adrenal axis function. Life Sciences; 58: 1683–94.
Dinan, TG, Scott, LV (2005) Anatomy of melancholia: focus on hypothalamic–pituitary–adrenal axis overactivity and the role of vasopressin. Journal of Anatomy; 207: 259–64.
Dorovini-Zis, K, Zis, AP (1987) Increased adrenal weight in victims of violent suicide. American Journal of Psychiatry; 144: 1214–5.
French, JA, Fite, JE, Jensen, H et al (2007) Treatment with CRH-1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii). American Journal of Primatology; 69: 877–89.
Gallagher, P, Watson, S, Smith, MS et al (2005) Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biological Psychiatry; 57: 155–61.
Gallagher, P, Malik, N, Newham, J et al (2008) Antiglucocorticoid treatments for mood disorders. Cochrane Database of Systematic Reviews; issue 1: CD005168.
Gartside, SE, Leitch, MM, Young, AH (2003) Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. Neuropsychopharmacology; 28: 1572–8.
Glezer, I, Rivest, S (2004) Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist; 10: 538–52.
Goldstein, ET, Preskorn, SH (1989) Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder. American Journal of Psychiatry; 146: 1076–7.
Harmer, CJ, Bhagwagar, Z, Shelley, N et al (2003) Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology; 167: 112–4.
Huffman, JC, Stern, TA (2007) Neuropsychiatric consequences of cardiovascular medications. Dialogues in Clinical Neurosciences; 9: 2945.
Hunt, PJ, Gurnell, EM, Huppert, FA et al (2000) Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. Journal of Clinical Endocrinology and Metabolism; 85: 4650–6.
Jahn, H, Schick, M, Kiefer, F et al (2004) Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Archives of General Psychiatry; 61: 1235–44.
Karssen, AM, Meijer, OC, Berry, A et al (2005) Low doses of dexamethasone can produce a hypocorticosteroid state in the brain. Endocrinology; 146: 5587–95.
Kunugi, H, Ida, I, Owashi, T et al (2006) Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic–pituitary–adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology; 31: 212–20.
Lester, D (1992) The dexamethasone suppression test as an indicator of suicide: a meta-analysis. Pharmacopsychiatry; 25: 265–70.
Lewis, LD, Cochrane, GM (1983) Psychosis in a child inhaling budesonide. Lancet; 2 (8350): 634.
Lopez, JF, Palkovits, M, Arato, M et al (1992) Localization and quantification of pro-opiomelanocortin mRNA and glucocorticoid receptor mRNA in pituitaries of suicide victims. Neuroendocrinology; 56: 491501.
Lupien, SJ, McEwen, BS (1997) The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Research Reviews; 24: 127.
Man, MS, Young, AH, McAllister-Williams, RH (2002) Corticosterone modulation of somatodendritic 5-HT1A receptor function in mice. Journal of Psychopharmacology; 16: 245–52.
McQuade, R, Young, AH (2000) Future therapeutic targets in mood disorders: the glucocorticoid receptor. British Journal of Psychiatry; 177: 390–5.
Mendelson, SD, McEwen, BS (1992) Quantitative autoradiographic analyses of the time course and reversibility of corticosterone-induced decreases in binding at 5-HT1A receptors in rat forebrain. Neuroendocrinology; 56: 881–8.
Meyboom, RH, De Graaf-Breederveld, N (1988) Budesonide and psychic side effects. Annals of Internal Medicine; 109: 683.
Murphy, BE, Filipini, D, Ghadirian, AM (1993) Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. Journal of Psychiatry and Neuroscience; 18: 209–13.
Murphy, BE (1997) Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology; 22 (suppl 1): s12532.
Nelson, JC, Davis, JM (1997) DST studies in psychotic depression: a meta-analysis. American Journal of Psychiatry; 154: 1497–503.
Nemeroff, CB, Owens, MJ, Bissette, G et al (1988) Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Archives of General Psychiatry; 45: 577–9.
Ormiston, T, Wolkowitz, OM, Reus, VI et al (2004) Hormonal changes with cholesterol reduction: a double-blind pilot study. Journal of Clinical Pharmacy and Therapeutics; 29: 71–3.
Pfennig, A, Kunzel, HE, Kern, N et al (2005) Hypothalamus–pituitary–adrenal system regulation and suicidal behavior in depression. Biological Psychiatry; 57: 336–42.
Phelan, MC (1989) Beclomethasone mania. British Journal of Psychiatry; 155: 871–2.
Porter, RJ, Gallagher, P, Watson, S et al (2004) Corticosteroidserotonin interactions in depression: a review of the human evidence. Psychopharmacology; 173: 117.
Raadsheer, FC, van Heerikhuize, JJ, Lucassen, PJ et al (1995) Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. American Journal of Psychiatry; 152: 1372–6.
Ravaris, CL, Sateia, MJ, Beroza, KW et al (1988) Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Archives of General Psychiatry; 45: 966–7.
Sapolsky, RM, Krey, LC, McEwen, BS (1986) The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocrine Reviews; 7: 284301.
Thompson, JM, Gallagher, P, Hughes, JH et al (2005) Neurocognitive impairment in euthymic patients with bipolar affective disorder. British Journal of Psychiatry; 186: 3240.
Walder, DJ, Walker, EF, Lewine, RJ (2000) Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biological Psychiatry; 48: 1121–32.
Watson, S, Gallagher, P, Ritchie, JC et al (2004) Hypothalamic–pituitary–adrenal axis function in patients with bipolar disorder. British Journal of Psychiatry; 184: 496502.
Watson, S, Gallagher, P, Ferrier, IN et al (2006) Post-dexamethasone arginine vasopressin levels in patients with severe mood disorders. Journal of Psychiatric Research; 40: 353–9.
Webster, MJ, Knable, MB, O'Grady, J et al (2002) Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Molecular Psychiatry; 7: 985–94.
Westrin, A, Nimeus, A (2003) The dexamethasone suppression test and CSF-5-HIAA in relation to suicidality and depression in suicide attempters. European Psychiatry; 18: 166–71.
Wolkowitz, OM, Reus, VI, Weingartner, H et al (1990) Cognitive effects of corticosteroids. American Journal of Psychiatry; 147: 1297–303.
Wolkowitz, OM, Reus, VI, Keebler, A et al (1999) Double-blind treatment of major depression with dehydroepiandrosterone. American Journal of Psychiatry; 156: 646–9.
Yehuda, R (2001) Biology of posttraumatic stress disorder. Journal of Clinical Psychiatry; 62 (suppl 17): 41–6.
Yehuda, R (2006) Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. Annals of the New York Academy of Sciences; 1071: 137–66.
Young, AH (1994a) Glucocorticoids, serotonin and mood. British Journal of Psychiatry; 165: 271–2.
Young, AH, Sharpley, AL, Campling, GM et al (1994b) Effects of hydrocortisone on brain 5-HT function and sleep. Journal of Affective Disorders; 32: 139–46.
Young, AH, Sahakian, BJ, Robbins, TW et al (1999) The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology; 145: 260–66.
Young, AH, Gallagher, P, Porter, RJ (2002) Elevation of the cortisol–dehydroepiandrosterone ratio in drug-free depressed patients. American Journal of Psychiatry; 159: 1237–9.
Young, AH, Gallagher, P, Watson, S et al (2004) Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology; 29: 1538–45.
Young, EA, Breslau, N (2004a) Saliva cortisol in posttraumatic stress disorder: a community epidemiologic study. Biological Psychiatry; 56: 205–9.
Young, EA, Altemus, M, Lopez, JF et al (2004b) HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology; 29: 1198–204.
Zhou, DF, Shen, YC, Shu, LN, et al (1987) Dexamethasone suppression test and urinary MHPG X SO4 determination in depressive disorders. Biological psychiatry; 22: 883–91.
Zobel, AW, Nickel, T, Sonntag, A et al (2001) Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. Journal of Psychiatric Research; 35: 8394.

Antiglucocorticoids in psychiatry

  • Sean A. McIsaac, Åsa Westrin and Allan H. Young

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Antiglucocorticoids in psychiatry

  • Sean A. McIsaac, Åsa Westrin and Allan H. Young
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *